National Cancer Center, Japan
Also known as: Department of Gastrointestinal Medical Oncology, National cancer center hospital | Deputy Director for Research of the National Cancer Centre | Japan National Cancer Center Hospital | Kohei Shitara | Masahiro Tsuboi | National Cancer Center Hospital | National Cancer Center Hospital East | National Cancer Center Hospital East, Japan | National Cancer Center Hospital Tokyo, Japan | National Cancer Center Hospital, Tokyo JAPAN | National Cancer Center, Japan | National Cancer Centre Hospital, Tokyo
Highest phase reached
Phase 3
First clinical trial
May 1, 2004Last known activity
Jan 10, 2026
Timeline
1960s
- Jan 1, 1961
National Cancer Center, Japan— Founded
Drugs by trial phase (37 distinct, 34 trials)
Phase 3 (19 own, 0 via acquisition)
Phase 2 (15 own, 0 via acquisition)
Phase 1 (3 own, 0 via acquisition)
Indications
Studied for
- Breast Neoplasms
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Squamous Cell
- Colorectal Neoplasms
- Enuresis
- Esophageal Neoplasms
- Esophageal Squamous Cell Carcinoma
- Leukemia
- Leukemia, Lymphoid
- Lung Neoplasms
- Lymphoma
- Lymphoma, Non-Hodgkin
- Neoplasms
- Ovarian Neoplasms
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Stomach Neoplasms
- Urinary Incontinence
- Uterine Cervical Neoplasms
Recent trials (50)
- NCT07292207CollaboratorPhase 2Jan 10, 2026
- NCT07287748OfficialPhase 1Jan 1, 2026
- NCT07018570Lead sponsorPhase 2Jul 24, 2025
- NCT07018570Sponsor investigatorPhase 2Jul 24, 2025
- NCT07100704Lead sponsorPhase 2Apr 15, 2025
- NCT06673628Lead sponsorPhase 2Dec 1, 2024
- NCT06940791CollaboratorPhase 2Oct 6, 2023
- NCT05832827Overall official - principal investigatorPhase 2Sep 4, 2023
- NCT05832827Lead sponsorPhase 2Sep 4, 2023
- NCT06159478Lead sponsorPhase 2Mar 29, 2023
- NCT05646511Lead sponsorPhase 3Nov 21, 2022
- NCT05646511Reponsible party - principal investigatorPhase 3Nov 21, 2022
- NCT05394740Overall official - principal investigatorPhase 1/Phase 2Jun 6, 2022
- NCT05394740Lead sponsorPhase 1/Phase 2Jun 6, 2022
- NCT05394740Reponsible party - principal investigatorPhase 1/Phase 2Jun 6, 2022
Details
- Founded
- Tokyo, JP Jan 1, 1961
- Last known activity
- Jan 10, 2026